[go: up one dir, main page]

AU2001272461A1 - Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl) - Google Patents

Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)

Info

Publication number
AU2001272461A1
AU2001272461A1 AU2001272461A AU7246101A AU2001272461A1 AU 2001272461 A1 AU2001272461 A1 AU 2001272461A1 AU 2001272461 A AU2001272461 A AU 2001272461A AU 7246101 A AU7246101 A AU 7246101A AU 2001272461 A1 AU2001272461 A1 AU 2001272461A1
Authority
AU
Australia
Prior art keywords
triglyceride
pptrl
mtp
inhibitors
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001272461A
Other languages
English (en)
Inventor
Hilmar Bischoff
Rudi Grutzmann
Ulrich Muller
Siegfried Zaiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2001272461A1 publication Critical patent/AU2001272461A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AU2001272461A 2000-06-21 2001-06-08 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl) Abandoned AU2001272461A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10030375A DE10030375A1 (de) 2000-06-21 2000-06-21 Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
DE10030375.7 2000-06-21
PCT/EP2001/006526 WO2001097787A2 (de) 2000-06-21 2001-06-08 Verwendung von mtp-inhibitoren zur senkung von pptrl

Publications (1)

Publication Number Publication Date
AU2001272461A1 true AU2001272461A1 (en) 2002-01-02

Family

ID=7646394

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001272461A Abandoned AU2001272461A1 (en) 2000-06-21 2001-06-08 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)

Country Status (7)

Country Link
US (2) US20040014748A1 (de)
EP (1) EP1296681A2 (de)
JP (1) JP2003535888A (de)
AU (1) AU2001272461A1 (de)
CA (1) CA2413277A1 (de)
DE (1) DE10030375A1 (de)
WO (1) WO2001097787A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
KR20050008752A (ko) * 2002-05-31 2005-01-21 야마노우치세이야쿠 가부시키가이샤 테트라히드로피란 유도체
CA2910191C (en) 2004-03-05 2022-03-08 The Trustees Of The Univeristy Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
WO2006093932A2 (en) * 2005-03-01 2006-09-08 Cedars-Sinai Medical Center Use of eotaxin as a diagnostic indicator for atherosclerosis and vascular inflammation
US20070015179A1 (en) * 2005-04-26 2007-01-18 Trustees Of Boston University Plastic microfluidic chip and methods for isolation of nucleic acids from biological samples
JP2009511634A (ja) * 2005-10-18 2009-03-19 エージェリオン ファーマシューティカルズ 哺乳動物において高脂血症に関連する障害を治療する方法
CA2652751A1 (en) * 2006-05-18 2007-11-29 Bayer Healthcare Ag Pharmaceutical compositions and methods of using same
EP2059241A1 (de) * 2006-09-05 2009-05-20 Schering Corporation Pharmazeutische kombinationen für die lipidverwaltung und die behandlung von atherosklerose und hepatischer steatose
WO2008079398A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
WO2009158375A1 (en) * 2008-06-25 2009-12-30 Abbott Laboratories Aza-cylic indole- 2 -carboxamides and methods of use thereof
CA2760516A1 (en) 2009-04-29 2011-02-17 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
EP4008327A1 (de) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmazeutische zusammensetzungen mit epa und einem kardiovaskulären mittel sowie verfahren zur verwendung davon
US9255094B2 (en) 2009-04-29 2016-02-09 Medivation Technologies, Inc. Pyrido[4,3-B]indoles and methods of use
IN2013MN01699A (de) 2011-02-18 2015-06-12 Medivation Technologies Inc
US20230285376A1 (en) 2020-07-29 2023-09-14 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (de) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4499289A (en) * 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4871721A (en) * 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
US4924024A (en) * 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
KR930005040B1 (ko) * 1989-08-31 1993-06-12 주식회사 금성사 식기 건조기 겸용 전자레인지 및 그 구동제어방법
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
DE19546919A1 (de) * 1995-12-15 1997-06-19 Bayer Ag N-Heterocyclisch substituierte Phenylessigsäure-Derivate
DE19613550A1 (de) * 1996-04-04 1997-10-09 Bayer Ag Neue Pyrimido[1,2-a]indole
DE19615265A1 (de) * 1996-04-18 1997-12-04 Bayer Ag Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole
US5827875A (en) * 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
AU727895B2 (en) * 1997-01-17 2001-01-04 Bristol-Myers Squibb Company Method for treating atherosclerosis with an MPT inhibitor and cholesterol lowering drugs
DE19929065A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19929031A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
DE19951022A1 (de) * 1999-10-22 2001-04-26 Bayer Ag Carbolinderivate

Also Published As

Publication number Publication date
DE10030375A1 (de) 2002-01-03
WO2001097787A3 (de) 2002-11-14
US20040014748A1 (en) 2004-01-22
JP2003535888A (ja) 2003-12-02
WO2001097787A2 (de) 2001-12-27
CA2413277A1 (en) 2001-12-27
US20060166999A1 (en) 2006-07-27
EP1296681A2 (de) 2003-04-02

Similar Documents

Publication Publication Date Title
AU2001272461A1 (en) Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl)
AU2002315857A1 (en) Cell proliferation inhibitors containing anti-glypican 3 antibody
AU2002213485A1 (en) Inhibitors of protein kinases
AU2002334355A1 (en) Protein tyrosine kinase inhibitors
AUPR392301A0 (en) Protein phosphatase inhibitors
AU2002316137A1 (en) Method of determining protein interaction inhibitors
AU2003282891A1 (en) Novel tyrosine kinases inhibitors
AU4543899A (en) Multibinding inhibitors of microsomal triglyceride transferase protein
AU2003286311A1 (en) Microsomal triglyceride transfer protein inhibitors
AU2002361589A1 (en) Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
AU2003275282A1 (en) Novel tyrosine kinase inhibitors
AU2002953255A0 (en) Protein kinase inhibitors
AU2002230385A1 (en) Peptide deformylase inhibitors
AU2003286347A1 (en) Microsomal triglyceride transfer protein inhibitors
EG24516A (en) Peptide deformylase inhibitors
AUPS251502A0 (en) Protein kinase inhibitors
AU2003296960A1 (en) Peptide deformylase inhibitors
EP1383729A4 (de) Peptiddeformylaseinhibitoren
AU2001280540A1 (en) Inhibitors of plant peptide deformylase for use as broad-spectrum herbicides and methods for identifying the same
AU2002305868A1 (en) Inhibitors of reggamma
AU2002342417A1 (en) Inhibitors of dna methyltransferase isoforms
GB0109278D0 (en) Enzyme inhibitors
AU2001233723A1 (en) Utilization of protein kinase inhibitor alpha
AU2003245423A1 (en) Peptide deformylase inhibitors
AU2002215161A1 (en) An assay for rhabdovirus inhibitors